EP1608661A2 - Herstellverfahren für 7-(p-hydroxyphenylglycylamido)cephem-verbindungen - Google Patents
Herstellverfahren für 7-(p-hydroxyphenylglycylamido)cephem-verbindungenInfo
- Publication number
- EP1608661A2 EP1608661A2 EP04722335A EP04722335A EP1608661A2 EP 1608661 A2 EP1608661 A2 EP 1608661A2 EP 04722335 A EP04722335 A EP 04722335A EP 04722335 A EP04722335 A EP 04722335A EP 1608661 A2 EP1608661 A2 EP 1608661A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- alkyl
- group
- methyl
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D501/06—Acylation of 7-aminocephalosporanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
Definitions
- the field of the invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
- the invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
- 7- amino (p-hydroxyphenylglycyl) cephem compounds such as cefprozil, cefadroxil and cefatrizine are generally prepared by reacting a cephem derivative with a reactive derivative, such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
- a reactive derivative such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
- British Patent GB 1,240,687 discloses a process involving reacting N-protected 4- hydroxyplienylglycine with ethyl chloroformate to obtain a carbonate derivative which is acylated with a cephem compound.
- this method gives a product of low purity.
- a major impurity formed in such a process has the structure of Formula A,
- R is a group commonly used at the 3-position in cephalosporins, for example, methyl, 1-propenyl and l,2,3-triazol-5-yl tbiornethyl.
- the present invention provides a process which results in pure 7- amino (p- hydroxyphenylglycyl) cephem compounds.
- the process of the present invention avoids purification by tedious and cumbersome processes.
- the process of the present invention reduces the impurity content of the final product, eliminates the costly and time- consuming purification steps.
- R is a group commonly used at the 3-position in cephalosporins and may include C 1 6 alkyl, C 2 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . h particular, it may include methyl, 1- propenyl and l,2,3-triazol-5-yl thiomethyl.
- compositions and dosage forms containing a therapeutically effective amount of the cephem compounds of Formula I and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of bacterial infections.
- a method of treating bacterial infections comprising administering to a mammal in need thereof, a therapeutically effective amount of cephem compounds of Formula I as described above.
- R is a group commonly used at the 3 -position in cephalosporins and includes C l g alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 _ 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . hi particular, it includes methyl, 1- propenyl and l,2,3-triazol-5-yl tl iomethyl.
- the process comprising:
- R' is C 1-4 alkyl and M + is an alkali metal cation
- R is C 1 6 alkyl, C,_ 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,
- the preparation of the mixed anhydride is carried out in the presence of a small amount of an acid to minimize the formation of impurity of Formula B, in the step ii) reaction,
- R is a group commonly used at the 3-position in cephalosporins, and includes C. 6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl.
- the process is useful for the preparation of a wide variety of 7- amino(p- hydroxyphenylglycyl) -cephalosporins, for example, cefatrizine, cefadroxil, or cefprozil, in good yield and purity.
- Examples of Dane salts of Formula III include sodium or potassium D-N-(l- methoxycarbonylpropen-2-yl)amino-p-hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)-amino-p-hydroxyphenylacetate.
- Examples of alkyl chloro formates include ethyl chloroformate and methyl chloroformate.
- Examples of amines present as a catalyst for mixed carboxylic acid anhydride formation include N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
- the mixed anhydride may be prepared in one or more solvents, including, for example, halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, amide and mixtures thereof.
- chlorinated hydrocarbons include dichoromethane and dichloroethylene;
- ketones include acetone and methyl isobutyl ketone;
- ester include ethyl acetate and isopropylacetate;
- Examples of ether include tetrahydrofuran and dioxane; a nitrile includes acetonitrile;
- aromatic hydrocarbon include toluene.
- a suitable co-solvent may be used with a solvent, for example amide.
- a suitable amide includes one or more of formamide, acetamide, N,N- dimethyl formamide, N-methylacetamide, N,N-dimethylacetamide and N- methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
- the formation of the mixed carboxylic acid anhydride may be carried out at temperatures, from about -80°C to about 50°C, or from about -50°C to about 5°C.
- step i) is generally obtained as a solution or a suspension of the mixed carboxylic acid anhydride, and can be further used as such. If desired, this anhydride may be maintained at from about -60°C to about -20°C.
- the 7-amino-ceph-3-em-4-carboxylic acid of Formula II maybe silylated with silylation agents in a solvent inert under the reaction conditions.
- silylation agents include mono- or bissilylated amides, such as N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl-acetamide (MSA); silylated ureas, such as N,N'-bis- (trimethylsilyl)-urea (BSU); or silazanes, such as 1 1 3,3,3- hexamethyldisilazane (HMDS), in combination with a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such as triethylamine, tert.octylamine.
- a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such
- the solvents used for mixed anhydride preparation above may be used for silylation of the 7-amino-ceph-3-em-4-carboxylic acid, and also for the step ii) reaction.
- the reaction temperatures for the step ii) may be from about -60°C to room temperature or from about -40 ° C to about -10°C.
- the reaction mixture of the step ii) may be worked up in a conventional manner.
- the substituted vinyl group may be split by hydrolysis in aqueous acid.
- the final product may be isolated in a conventional manner, for example by adjusting the pH of the reaction mixture.
- the product of Formula I can be obtained in a very high purity, for example above 98%.
- the 7-amino-ceph-3-em-4-carboxylic acid of Formula II may be prepared in accordance with any of the known methods (see U.S. Patent Nos. 3,867,380; 3 489,752 and 4,520,022).
- the Dane salt of Formula III may be obtained from commercial sources or prepared by methods well known in the art.
- compounds of Formula I having less than 0.5% by weight of the impurity of Formula B can be obtained.
- compounds of Formula I having less than 0.1% by weight of the impurity of Formula B, or less than 0.05% can be obtained.
- the resulting cephem compounds of Formula I may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. hi these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
- compositions include dosage forms suitable for oral and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration.
- the oral dosage forms may include solid dosage forms, like powder, tablets, capsules, as well as liquid suspensions.
- Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
- the suspension of silylated 7-APCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
- a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
- the aqueous layer was diluted with dimethylformamide(700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
- the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
- the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 98g of cefprozil as dimethyl formamide (1.5 mole) solvate.
- the suspension of silylated 7-ADCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
- a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
- the aqueous layer was diluted with dimethylformamide (700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
- the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
- the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 105g of cefadroxil as dimethyl formamide (1.5 mole) solvate.
- cefadroxil dimethyl formamide solvate was converted to white crystalline solid cefadroxil monohydrate by the procedure reported in U.S. Patent No. 4,504,657.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INDE03532003 | 2003-03-21 | ||
IN353DE2003 | 2003-03-21 | ||
PCT/IB2004/000850 WO2004083172A2 (en) | 2003-03-21 | 2004-03-22 | Process for the preparation of 7-amino (p-hydroxyphenylglyclyamido) cephem compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1608661A2 true EP1608661A2 (de) | 2005-12-28 |
Family
ID=33017825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04722335A Withdrawn EP1608661A2 (de) | 2003-03-21 | 2004-03-22 | Herstellverfahren für 7-(p-hydroxyphenylglycylamido)cephem-verbindungen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1608661A2 (de) |
CA (1) | CA2519853A1 (de) |
WO (1) | WO2004083172A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048887A1 (en) | 2004-11-01 | 2006-05-11 | Hetero Drugs Limited | A novel process for preparation of cefprozil intermediate |
CN102408438B (zh) * | 2010-09-26 | 2015-01-07 | 石药集团中奇制药技术(石家庄)有限公司 | 一种头孢丙烯一水合物的制备方法 |
CN102443013B (zh) * | 2010-10-10 | 2014-09-17 | 石药集团中奇制药技术(石家庄)有限公司 | 一种头孢丙烯二甲基甲酰胺溶剂化物的制备方法 |
CN102911187B (zh) * | 2012-10-11 | 2015-03-11 | 南通康鑫药业有限公司 | 一种头孢丙烯的回收方法 |
CN112694487B (zh) * | 2020-12-29 | 2022-04-22 | 苏州盛达药业有限公司 | 一种头孢丙烯的制备方法 |
CN113533591B (zh) * | 2021-06-18 | 2022-08-23 | 山东罗欣药业集团恒欣药业有限公司 | 一种头孢丙烯中苯和三聚乙醛的gc分析方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899394A (en) * | 1972-12-26 | 1975-08-12 | Bristol Myers Co | Production of antibacterial agents |
FR2215939B1 (de) * | 1973-01-31 | 1976-07-02 | Roussel Uclaf | |
GB1505345A (en) * | 1974-04-10 | 1978-03-30 | Beecham Group Ltd | Cephalosporins |
US4148817A (en) * | 1976-03-25 | 1979-04-10 | Eli Lilly And Company | Process and intermediates for preparing cephalosporin antibiotics |
IT1065387B (it) * | 1976-12-16 | 1985-02-25 | Dobfar Spa | Proccedimento per la preparazione di cefalosporine |
KR820001564B1 (ko) * | 1981-05-09 | 1982-09-02 | 동신제약 주식회사 | 새로운 실릴화제를 이용한 세팔로스포린 유도체의 제조방법 |
US20040077849A1 (en) * | 2002-10-16 | 2004-04-22 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of cefadroxil |
US6903211B2 (en) * | 2002-10-30 | 2005-06-07 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of 3-propenyl cephalosporin DMF solvate |
-
2004
- 2004-03-22 EP EP04722335A patent/EP1608661A2/de not_active Withdrawn
- 2004-03-22 WO PCT/IB2004/000850 patent/WO2004083172A2/en not_active Application Discontinuation
- 2004-03-22 CA CA002519853A patent/CA2519853A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004083172A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004083172A2 (en) | 2004-09-30 |
WO2004083172A3 (en) | 2004-12-02 |
CA2519853A1 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6552186B2 (en) | β-lactam production | |
US7427692B2 (en) | Process for preparation of 7-[α-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | |
EP0233271B1 (de) | Herstellungsverfahren von cephalosporin-zwischenprodukten | |
US5461043A (en) | Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate | |
EP1068211B1 (de) | Verfahren zur reinigung eines cephalosporin-derivats | |
EP1608661A2 (de) | Herstellverfahren für 7-(p-hydroxyphenylglycylamido)cephem-verbindungen | |
EP1389187A2 (de) | Verfahren zur herstellung von cefpodoximsäure | |
EP1773845A1 (de) | Verfahren zur herstellung reiner cephalosporinzwischenprodukte | |
US5998610A (en) | Silylation process | |
CZ282160B6 (cs) | Způsob přípravy cefalosporinového antibiotika | |
RO109652B1 (ro) | Procedeu pentru prepararea unui antibiotic cefepim dihidroclorura hidrat | |
EP1809638B1 (de) | Neues verfahren zur herstellung eines cefprozil-zwischenprodukts | |
US4868294A (en) | Process for preparing cephalosporin intermediates | |
KR920001769B1 (ko) | 클로로세파드록실 모노하이드레이트의 제조방법 | |
JP4616844B2 (ja) | セファロスポリン合成に使用するための中間体の生成プロセス | |
KR840002046B1 (ko) | 세팔로스포린의 제조방법 | |
WO2005040175A2 (en) | Process for the preparation of cephem carboxylic acids | |
US20040077849A1 (en) | Process for the preparation of cefadroxil | |
US20050267092A1 (en) | Novel cephalosporin compounds and process for preparing the same | |
EP1299396A1 (de) | Neue cephalosporin-verbindungen und verfahren zu deren herstellung | |
AU2002307885A1 (en) | Process for the preparation of cefpodoxime acid | |
MXPA96005773A (en) | Cephalosporine compounds and processes for the preparation of mis | |
JPH0322391B2 (de) | ||
JPS6117837B2 (de) | ||
JPH10182656A (ja) | セフェム化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051021 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071002 |